Alumis Inc.

Contributing Author

Recent Articles by Alumis Inc.

8 hours	Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) ALMS -56.81% GlobeNewswire
Aug-13	Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements ALMS GlobeNewswire
Aug-10	Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies ALMS ALMS -7.85% GlobeNewswire
May-14	Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements ALMS ALMS -7.15% GlobeNewswire
Mar-28	Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis ALMS GlobeNewswire
Mar-19	Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements ALMS GlobeNewswire
Mar-18	Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting ALMS GlobeNewswire
Mar-02	Alumis to Present at the Leerink Partners Global Healthcare Conference ALMS GlobeNewswire
Feb-05	Alumis to Participate in Upcoming February Investor Conferences ALMS GlobeNewswire
Jan-09	Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares ALMS +7.59% ALMS +7.82% GlobeNewswire
Jan-07	Alumis Announces Pricing of Upsized Public Offering of Common Stock ALMS GlobeNewswire
Jan-06	Alumis Announces Proposed Public Offering of Common Stock ALMS +95.31% GlobeNewswire
Jan-06	Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program ALMS +95.31% GlobeNewswire
Jan-05	Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis ALMS -7.20% GlobeNewswire
Nov-13	Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress ALMS GlobeNewswire
Nov-04	Alumis to Participate in Upcoming November Investor Conferences ALMS GlobeNewswire
Aug-29	Alumis to Participate in Upcoming September Investor Conferences ALMS GlobeNewswire
Aug-13	Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update ALMS GlobeNewswire
Jul-24	Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus ALMS GlobeNewswire
Jul-14	Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary ALMS GlobeNewswire
May-29	Alumis to Present at the Jefferies Global Healthcare Investor Conference ALMS ALMS -10.49% GlobeNewswire
May-29	Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis ALMS GlobeNewswire
May-21	Alumis Completes Merger with ACELYRIN ALMS GlobeNewswire
May-14	Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements ALMS ALMS +18.63% GlobeNewswire
May-13	Alumis Stockholders Approve Merger with ACELYRIN ALMS -15.05% GlobeNewswire

Alumis Inc.

Recent Articles by Alumis Inc.

Upgrade your Finviz experience